Type 1 Diabetes

Drs Diana Isaacs and Natalie Bellini discuss the everyday challenges of managing type 1 diabetes and underscore the need for new treatments to improve the quality of life for people living with type 1 diabetes

Expert healthcare practitioners discuss the potential of CGM and other technology to identify signs of type 1 diabetes.

Dr Emily Sims reviews the study design of the clinical trials with teplizumab and shares key findings from the completed phase 2 trial.

Dr Emily Sims provides an overview of the stages of type 1 diabetes (T1D) and explains how teplizumab slows the immune-mediated destruction of beta cells.

A systematic review of nearly 100 published studies provides an overview of sex-based disparities in the care of pediatric patients with type 1 diabetes.

The January 2023 endocrinology month in review features coverage of the FDA’s approval of bexagliflozin, news surrounding semaglutide, and the introduction of an expert-led, diabetes-focused podcast to HCPLive Endocrinology.

In this episode of Diabetes Dialogue, ours hosts discuss the clearance of Tidepool Loop, what is unique about the app’s customizability and compatibility with other diabetes technologies, and other top points for people with diabetes and members of the diabetes care team to consider with the technology moving into the future.

A study of more than 100 adults with type 1 diabetes suggests those with increased levels of self-stigma had worse glucose control than their counterparts with lower levels of self-stigma.

Abbott's Proclaim XR spinal cord stimulation system allows patients with painful diabetic peripheral neuropathy to improve quality of life using a system that is easily incorporated into their everyday lives.

Announced on January 24, the US FDA's marketing clearance for the Tidepool Loop mobile app allows for use with compatible devices for automated insulin dosing to help manage type 1 diabetes in persons 6 years of age and older.

A prospective, dual-center study of people with high-risk type 1 diabetes using multiple daily injections aged 13-25 years demonstrates the utility of this technology in this patient population.

To celebrate the end of 2022 and the advances witnessed in the past year, our editorial team has created a list of the top 8 most popular pieces of content related to endocrinology from 2022.

To commemorate the inaugural year and the success of Diabetes Dialogue in 2022, our editorial team has compiled a list of the 5 most popular episodes from the past year. Further in this article, we offer readers a look into each of our hosts top picks for episodes during 2022.

In the December 2022 episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss recent developments in the field, with a spotlight on the Dexcom G7 CGM, key takeaways from the ADA’s Standards of Care in Diabetes—2023, and perspective from the ADCES Diabetes Technology Conference 2022.

In this episode of Diabetes Dialogue, Jill Weissberg-Benchell, PhD, takes hosts through her journey to becoming a diabetes care and education specialist, the role of psychologists in the management of pediatric diabetes, and her thoughts on the evolving role of care and education specialists in the management of diabetes.

In this episode of Diabetes Dialogue, Richard Bergenstal, MD, sits down with hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss the role and evolution of technology in the management of diabetes.

An analysis of NHANES data spanning more than 3 decades provides an overview of trends in glycemic control and severe hyperglycemia among people with diabetes using insulin, including racial and ethnic disparities.

In this episode of Diabetes Dialogue, Jane Jeffrie Seley, DNP, MPH, a member of the writing committee for the ADA's Standards of Care in Diabetes—2023, joins the podcast to discuss pertinent updates in the sections of the document discussing inpatient management of diabetes within the document.

A recent survey found that most people with type 1 diabetes felt their coaches, trainers, and teachers treated them differently after learning about their diagnosis. In this column, Fran Damian, MS, RN, provides 3 simple steps to better support athletes with diabetes.

The November 2022 endocrine month in review features coverage of the FDA’s approval of teplizumab, new data related to use of GLP-1 receptor agonists, and a trio of stories on topics pertaining to diabetes technology.

A Johns Hopkins-led analysis provides a snapshot of trends in racial disparities seen in both uptake of and engagement in discussions with providers around continuous glucose monitoring and insulin pumps among adults with type 1 diabetes.

In this special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, break down what the approval of teplizumab means for type 1 diabetes. During the episode, hosts take a deep dive into type 1 diabetes staging and hypothesize around the role of CDCES in educating primary care and other specialties to optimize the potential of teplizumab.

In this episode, our hosts are joined by Lydia Alexander, MD, president-elect of the Obesity Medicine Association, to discuss the updates in the landscape of obesity management as well as a deep dive into the recent American Gastroenterological Association guidelines for pharmacological management and the OMA's annual meeting.

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the ongoing GLP-1 RA shortage and whether or not celebrities using these agents for weight loss is a real issue in the community as well as provide insight into their top takeaways from the ADA/KDIGO consensus report.

In this special edition episode of Diabetes Dialogue, our hosts break down their top clinical takeaways from the European Association for the Study of Diabetes 2022 annual meeting, new data from the FLASH-UK trial, the global launch of Dexcom G7, and the announcement of US availability for the FreeStyle Libre 3.